Skip to main content
SpringerLink
Log in

Dissolution Studies of Poorly Soluble Drug Nanosuspensions in Non-sink Conditions

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

Sink conditions used in dissolution tests lead to rapid dissolution rates for nanosuspensions, causing difficulties in discriminating dissolution profiles between different formulations. Here, non-sink conditions were studied for the dissolution testing of poorly water-soluble drug nanosuspensions. A mathematical model for polydispersed particles was established to clarify dissolution mechanisms. The dissolution of nanosuspensions with either a monomodal or bimodal size distribution was simulated. In the experimental part, three different particle sizes of indomethacin nanosuspensions were prepared by the wet milling technique. The effects of the dissolution medium pH and agitation speed on dissolution rate were investigated. The dissolution profiles in sink and non-sink conditions were obtained by changing the ratio of sample amount to the saturation solubility. The results of the simulations and experiments indicated that when the sample amount was increased to the saturation solubility of drug, the slowest dissolution rate and the best discriminating dissolution profiles were obtained. Using sink conditions or too high amount of the sample will increase the dissolution rate and weaken the discrimination between dissolution profiles. Furthermore, the low solubility by choosing a proper pH of the dissolution medium was helpful in getting discriminating dissolution profiles, whereas the agitation speed appeared to have little influence on the dissolution profiles. This discriminatory method is simple to perform and can be potentially used in any nanoproduct development and quality control studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

REFERENCES

  1. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev. 2010;62:491–502.

    Article  PubMed  CAS  Google Scholar 

  2. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 2011;16:354–60.

    Article  PubMed  CAS  Google Scholar 

  3. Date AA, Patravale VB. Current strategies for engineering drug nanoparticles. Curr Opin Colloid Interface Sci. 2004;9:222–35.

    Article  CAS  Google Scholar 

  4. Müller RH, Keck CM. Twenty years of drug nanocrystals: where are we, and where do we go? Eur J Pharm Biopharm. 2012;80:1–3.

    Article  PubMed  Google Scholar 

  5. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364(1):64–75.

    Article  PubMed  Google Scholar 

  6. Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int J Pharm. 1998;160(2):229–37.

    Article  Google Scholar 

  7. Krishna R, Yu L. Biopharmaceutics applications in drug development. 3rd ed. New York: Springer; 2008.

    Book  Google Scholar 

  8. Liu P, Rong X, Laru J, Van Veen B, Kiesvaara J, Hirvonen J, et al. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int J Pharm. 2011;411:215–22.

    Article  PubMed  CAS  Google Scholar 

  9. Ambrus R, Kocbek P, Kristl J, Sibanc R, Rajkó R, Szabó-Révész P. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. Int J Pharm. 2009;381(2):153–9.

    Article  PubMed  CAS  Google Scholar 

  10. Ganta S, Paxton JW, Baguley BC, Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm. 2009;367:179–86.

    Article  PubMed  CAS  Google Scholar 

  11. Sylvestre JP, Tang MC, Furtos A, Leclair G, Meunier M, Leroux JC. Nanonization of megestrol acetate by laser fragmentation in aqueous milieu. J Contr Release. 2011;149(3):273–80.

    Article  CAS  Google Scholar 

  12. Tucker CJ. Real time monitoring of small particle dissolution by way of light scattering. US Patent; 2004.

  13. Crisp MT, Tucker CJ, Rogers TL, Williams III RO, Johnston KP. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. J Contr Release. 2007;117(3):351–9.

    Article  CAS  Google Scholar 

  14. Peeters K, De Maesschalck R, Bohets H, Vanhoutte K, Nagels L. In situ dissolution testing using potentiometric sensors. Eur J Pharm Sci. 2008;34:243–9.

    Article  PubMed  CAS  Google Scholar 

  15. Kayaert P, Li B, Jimidar I, Rombaut P, Ahssini F, Van den Mooter G. Solution calorimetry as an alternative approach for dissolution testing of nanosuspensions. Eur J Pharm Biopharm. 2010;76(3):507–13.

    Article  PubMed  CAS  Google Scholar 

  16. Bhardwaj U, Burgess DJ. A novel USP apparatus 4 based release testing method for dispersed systems. Int J Pharm. 2010;388:287–94.

    Article  PubMed  CAS  Google Scholar 

  17. Siewert M, Dressman J, Brown CK, Shah VP. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech. 2003;4(1):article 7.

  18. Fogler HS. Elements of chemical reaction engineering. 3rd ed. Upper Saddle River: Prentice Hall PTR; 1999.

    Google Scholar 

  19. Frössling N. Über die Verdunstung fallender Tropfen. Gerl Beitr Geophys. 1938;52:170–216.

    Google Scholar 

  20. Higuchi WI, Hiestand EN. Dissolution rates of finely divided drug powders I. Effect of a distribution of particle sizes in a diffusion-controlled process. J Pharm Sci. 1963;52:67–71.

    Article  PubMed  CAS  Google Scholar 

  21. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm. 1989;51:9–17.

    Article  CAS  Google Scholar 

  22. Wang Y, Abrahamsson B, Lindfors L, Brasseur JG. Comparison and analysis of theoretical models for diffusion-controlled dissolution. Mol Pharm. 2012;9(5):1052–66.

    PubMed  CAS  Google Scholar 

  23. Laaksonen T, Liu P, Rahikkala A, Peltonen L, Kauppinen EI, Hirvonen J, et al. Intact nanoparticulate indomethacin in fast-dissolving carrier particles by combined wet milling and aerosol flow reactor methods. Pharm Res. 2011;28(10):2403–11.

    Article  PubMed  CAS  Google Scholar 

  24. Cerdeiraa AM, Mazzottib M, Ganderc B. Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability. Int J Pharm. 2010;396:210–8.

    Article  Google Scholar 

  25. Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol. 2010;62(11):1569–79.

    Article  PubMed  CAS  Google Scholar 

  26. Dolenc A, Kristl J, Baumgartner S, Planinsek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm. 2009;376:204–12.

    Article  PubMed  CAS  Google Scholar 

  27. Jamzad S, Fassihi R. Role of surfactant and pH on dissolution properties of fenofibrate and glipizide—a technical note. AAPS PharmSciTech. 2006;7(2):Article 33.

  28. Nokhodchi A, Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J Pharm Pharm Sci. 2005;8(1):18–25.

    PubMed  CAS  Google Scholar 

  29. Agata Y, Iwao Y, Miyagishima A, Itai S. Novel mathematical model for predicting the dissolution profile of spherical particles under non-sink conditions. Chem Pharm Bull. 2010;58(4):511–5.

    Article  PubMed  CAS  Google Scholar 

  30. Anhalt K, Geissler S, Harms M, Weigandt M, Fricker G. Development of a new method to assess nanocrystal dissolution based on light scattering. Pharm Res. 2012;29(10):2887–901.

    Article  PubMed  CAS  Google Scholar 

  31. Dolenc A, Kristl J, Baumgartner S, Planinšek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm. 2009;376:204–12.

    Article  PubMed  CAS  Google Scholar 

  32. Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijnsa P, Van den Mooter G. Drying of crystalline drug nanosuspensions—the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci. 2008;35:127–35.

    Article  PubMed  Google Scholar 

  33. Limnell T, Heikkilä T, Santos HA, Sistonen S, Hellstén S, Laaksonen T, et al. Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles. Int J Pharm. 2011;416(1):242–51.

    PubMed  CAS  Google Scholar 

  34. Heng D, Cutler DJ, Chan HK, Yun J, Raper JA. What is a suitable dissolution method for drug nanoparticles? Pharm Res. 2008;25(7):1696–701.

    Article  PubMed  CAS  Google Scholar 

  35. Gupta A, Gaud RS, Ganga S. Development of discriminating dissolution method for an insoluble drug: nisoldipine. Int J Pharm Tech Res. 2010;2(1):931–9.

    CAS  Google Scholar 

  36. Sugano K. Theoretical comparison of hydrodynamic diffusion layer models used for dissolution simulation in drug discovery and development. Int J Pharm. 2008;363:73–7.

    Article  PubMed  CAS  Google Scholar 

Download references

ACKNOWLEDGMENTS

We acknowledge the financial support from Orion Pharma and China Scholarship Council. We thank Roy Siddall for providing language help.

Author information

Authors and Affiliations

  1. Division of Pharmaceutical Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland

    Peng Liu, Odile De Wulf, Jouni Hirvonen, Leena Peltonen & Timo Laaksonen

  2. Faculty of Pharmacy, Ghent University, Harelbekestraat 72, 9000, Ghent, Belgium

    Odile De Wulf

  3. Orion Pharma R&D, Formulation Research, P.O. Box 65, 02101, Espoo, Finland

    Johanna Laru, Teemu Heikkilä, Bert van Veen & Juha Kiesvaara

Authors
  1. Peng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Odile De Wulf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johanna Laru
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teemu Heikkilä
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bert van Veen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Juha Kiesvaara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jouni Hirvonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Leena Peltonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Timo Laaksonen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timo Laaksonen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, P., De Wulf, O., Laru, J. et al. Dissolution Studies of Poorly Soluble Drug Nanosuspensions in Non-sink Conditions. AAPS PharmSciTech 14, 748–756 (2013). https://doi.org/10.1208/s12249-013-9960-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-013-9960-2

KEY WORDS

Search

Navigation